Unknown PHASE4 INTERVENTIONAL 2-arm NCT03483779

Comparing Ginkgo Biloba Pills and Placebo in the Treatment of Coronary Heart Disease With Impaired Glucose Regulation

A Series of N-of-1 Trials of Comparing Ginkgo Biloba Pills and Placebo in the Treatment of Coronary Heart Disease With Impaired Glucose Regulation

Sponsor: Wanbangde Pharmaceutical Group Co., LTD

Conditions Ginkgo Biloba Extract Randomized Controlled Trial

Interventions Ginkgo biloba pills placebo pills

Updated 7 times since 2018 Last updated: Apr 25, 2018 Started: Apr 25, 2018 Primary completion: Dec 30, 2020 Completion: Jul 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03483779, this PHASE4 trial focuses on Ginkgo Biloba Extract and Randomized Controlled Trial and remains ongoing. Sponsored by Wanbangde Pharmaceutical Group Co., LTD, it has been updated 7 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE4
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE4

▶ Show 2 earlier versions

Jun 2018 — Sep 2020 [monthly]

Recruiting PHASE4
Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wanbangde Pharmaceutical Group Co., LTD
Xiyuan Hospital of China Academy of Chinese Medical Sciences

Data source: Xiyuan Hospital of China Academy of Chinese Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China